Franklin FTSE South Korea ETF vs Novavax Inc — how do they compare? Franklin FTSE South Korea ETF trades at $58.12 (market cap $1.83B), while Novavax Inc trades at $11.1 (market cap $1.82B). The key difference: Franklin FTSE South Korea ETF and Novavax Inc are close in size by market cap, and Franklin FTSE South Korea ETF is more actively traded (679,902 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 15 Days and Novavax Inc for 59 Days on average.
| FLKR | NVAX | |
|---|---|---|
Market Cap | $1.83B | $1.82B |
Volume | 679,902 | 6,198,505 |
Sector | Broad Market / Factor | Health |
52-Week High | $72.25 | $12.56 |
52-Week Low | $27.09 | $6.22 |
Typical Hold Time | 15 Days | 59 Days |
Enterprise Value | — | $1.39B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →